Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tobramycin
Drug ID BADD_D02232
Description Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms.[A232294] Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).[L32739, L32744, L32749]
Indications and Usage For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
Marketing Status Prescription; Discontinued
ATC Code J01GB01; S01AA12
DrugBank ID DB00684
KEGG ID D00063
MeSH ID D014031
PubChem ID 36294
TTD Drug ID D07BCT
NDC Product Code 47335-171; 68788-7252; 65162-914; 63187-973; 51927-0226; 68083-312; 49502-401; 0078-0630; 68071-2272; 51927-2375; 53002-9230; 60760-583; 36000-242; 17478-290; 61314-643; 61919-598; 70644-899; 55700-747; 0404-7196; 76420-092; 0078-0494; 0093-4085; 70518-1370; 45865-427; 68180-962; 20076-2006; 42513-0011; 81861-0030; 49502-346; 0065-0644; 51846-1012; 68083-241; 0078-0813; 68071-4537; 51552-1520; 24492-850; 67457-473; 72266-163; 24208-290; 11014-0233; 50090-3569; 67457-428; 0065-0643; 50090-0486; 59651-129; 57885-0002; 68083-254; 53002-9232; 68083-374; 67877-678; 71205-101; 53002-9231; 61919-642; 36000-244; 13985-604; 45865-119; 39822-0412; 63187-024; 70700-173; 49502-345; 11722-073; 72266-196; 68083-253; 17478-340; 0093-3750; 63187-902; 10122-820; 53002-9233; 70069-131
Synonyms Tobramycin | Nebramycin Factor 6 | Tobramycin Sulfate | Sulfate, Tobramycin | Obracin | Tobracin | Brulamycin | Nebcin | Nebicin
Chemical Information
Molecular Formula C18H37N5O9
CAS Registry Number 32986-56-4
SMILES C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Nephropathy toxicL-lactate dehydrogenase A chainP00338T150533820859; 3573418; 2352376; 6519582
Nephropathy toxicBeta-hexosaminidaseP87258Not Available3820859; 3573418; 2352376; 6519582
Nephropathy toxicLysozyme CP61626T105863820859; 3573418; 2352376; 6519582
Toxicity to various agents1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1Q9NQ66T26846Not Available
Toxicity to various agentsPhospholipase A2P04054T31479Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Keratitis06.04.02.0020.000619%
Lacrimation increased06.08.02.004--
Laryngeal pain22.02.05.036--
Laryngitis22.07.03.001; 11.01.13.001--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukocytosis01.02.01.002--
Leukoderma23.05.02.001--Not Available
Leukopenia01.02.02.001--Not Available
Liver disorder09.01.08.001--Not Available
Local reaction08.01.03.012--Not Available
Loss of consciousness17.02.04.004--Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.0020.001547%Not Available
Lung disorder22.02.07.0010.008665%Not Available
Lymphoma16.20.01.001; 01.12.01.0010.000161%Not Available
Malaise08.01.01.0030.010522%
Memory impairment17.03.02.003; 19.20.01.0030.001857%
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001--Not Available
Nephrolithiasis20.04.01.0020.001238%
Nephropathy toxic20.05.03.002; 12.03.01.0100.000928%Not Available
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neurotoxicity17.02.10.002; 12.03.01.011--Not Available
Obliterative bronchiolitis22.03.01.0120.000161%Not Available
Ocular hyperaemia06.04.05.0040.001238%Not Available
Oesophageal varices haemorrhage24.07.02.022; 07.12.01.003; 09.01.06.0040.000619%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages